Profile
Jens Bjørheim currently works at Zelluna ASA, as Chief Medical Officer.
Dr. Bjørheim also formerly worked at Pronova BioPharma ASA, as Medical Director from 2006 to 2008, AstraZeneca A, as Senior Medical Director-Oncology from 2013 to 2016, and Ultimovacs ASA, as Chief Medical Officer.
Dr. Bjørheim received his doctorate degree in 1999 from the University of Oslo and doctorate degree in 2003 from the University of Oslo.
Jens Bjørheim active positions
| Companies | Position | Start |
|---|
Former positions of Jens Bjørheim
| Companies | Position | End |
|---|---|---|
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Corporate Officer/Principal | 2015-12-31 |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Chief Tech/Sci/R&D Officer | 2007-12-31 |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Chief Tech/Sci/R&D Officer | - |
Training of Jens Bjørheim
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Health Technology |
University of Oslo
University of Oslo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
AstraZeneca A/S (Denmark)
AstraZeneca A/S (Denmark) Pharmaceuticals: MajorHealth Technology Develops and distributes pharmaceutical medicines | Health Technology |
Ultimovacs ASA
Ultimovacs ASA Pharmaceuticals: MajorHealth Technology Develops novel peptide based therapeutic cancer vaccine | Health Technology |
- Stock Market
- Insiders
- Jens Bjørheim
















